ACIU AC Immune SA

NASDAQ
$2.52

AC Immune SA (ACIU) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.5% since its last earnings release on August 5, 2026.

AC Immune SA Beat Consensus Estimates
Wednesday, August 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.22)
Rev est $1M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.69

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About AC Immune SA

AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.